vs
Side-by-side financial comparison of Silvercrest Asset Management Group Inc. (SAMG) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Vanda Pharmaceuticals Inc. is the larger business by last-quarter revenue ($57.2M vs $32.0M, roughly 1.8× Silvercrest Asset Management Group Inc.). Silvercrest Asset Management Group Inc. runs the higher net margin — -0.4% vs -246.8%, a 246.4% gap on every dollar of revenue. On growth, Vanda Pharmaceuticals Inc. posted the faster year-over-year revenue change (7.6% vs -0.0%). Silvercrest Asset Management Group Inc. produced more free cash flow last quarter ($15.0M vs $-29.5M). Over the past eight quarters, Vanda Pharmaceuticals Inc.'s revenue compounded faster (9.8% CAGR vs 2.7%).
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
SAMG vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.0M | $57.2M |
| Net Profit | $-120.0K | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | -70.5% |
| Net Margin | -0.4% | -246.8% |
| Revenue YoY | -0.0% | 7.6% |
| Net Profit YoY | -107.4% | -2774.3% |
| EPS (diluted) | $0.02 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $32.0M | $57.2M | ||
| Q3 25 | $31.3M | $56.3M | ||
| Q2 25 | $30.7M | $52.6M | ||
| Q1 25 | $31.4M | $50.0M | ||
| Q4 24 | $32.0M | $53.2M | ||
| Q3 24 | $30.4M | $47.7M | ||
| Q2 24 | $31.0M | $50.5M | ||
| Q1 24 | $30.3M | $47.5M |
| Q4 25 | $-120.0K | $-141.2M | ||
| Q3 25 | $618.0K | $-22.6M | ||
| Q2 25 | $1.9M | $-27.2M | ||
| Q1 25 | $2.5M | $-29.5M | ||
| Q4 24 | $1.6M | $-4.9M | ||
| Q3 24 | $2.3M | $-5.3M | ||
| Q2 24 | $2.7M | $-4.5M | ||
| Q1 24 | $3.0M | $-4.1M |
| Q4 25 | -2.8% | -70.5% | ||
| Q3 25 | 4.3% | -55.6% | ||
| Q2 25 | 13.2% | -73.2% | ||
| Q1 25 | 15.4% | -82.0% | ||
| Q4 24 | 6.1% | -19.3% | ||
| Q3 24 | 14.6% | -23.1% | ||
| Q2 24 | 17.1% | -20.1% | ||
| Q1 24 | 19.5% | -19.5% |
| Q4 25 | -0.4% | -246.8% | ||
| Q3 25 | 2.0% | -40.1% | ||
| Q2 25 | 6.3% | -51.7% | ||
| Q1 25 | 7.9% | -58.9% | ||
| Q4 24 | 5.1% | -9.2% | ||
| Q3 24 | 7.4% | -11.2% | ||
| Q2 24 | 8.6% | -9.0% | ||
| Q1 24 | 9.9% | -8.7% |
| Q4 25 | $0.02 | $-2.40 | ||
| Q3 25 | $0.07 | $-0.38 | ||
| Q2 25 | $0.21 | $-0.46 | ||
| Q1 25 | $0.26 | $-0.50 | ||
| Q4 24 | $0.16 | $-0.09 | ||
| Q3 24 | $0.24 | $-0.09 | ||
| Q2 24 | $0.28 | $-0.08 | ||
| Q1 24 | $0.32 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $44.1M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $50.3M | $327.2M |
| Total Assets | $166.6M | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $44.1M | $84.9M | ||
| Q3 25 | $36.1M | $70.0M | ||
| Q2 25 | $30.0M | $81.0M | ||
| Q1 25 | $36.3M | $111.8M | ||
| Q4 24 | $68.6M | $102.3M | ||
| Q3 24 | $58.1M | $100.5M | ||
| Q2 24 | $49.9M | $103.0M | ||
| Q1 24 | $39.7M | $125.2M |
| Q4 25 | $50.3M | $327.2M | ||
| Q3 25 | $58.9M | $466.0M | ||
| Q2 25 | $64.6M | $486.3M | ||
| Q1 25 | $80.0M | $511.4M | ||
| Q4 24 | $80.7M | $538.5M | ||
| Q3 24 | $84.6M | $541.2M | ||
| Q2 24 | $85.3M | $542.5M | ||
| Q1 24 | $83.9M | $544.0M |
| Q4 25 | $166.6M | $488.9M | ||
| Q3 25 | $157.6M | $601.1M | ||
| Q2 25 | $152.7M | $624.7M | ||
| Q1 25 | $159.9M | $631.9M | ||
| Q4 24 | $194.4M | $656.2M | ||
| Q3 24 | $184.2M | $645.1M | ||
| Q2 24 | $177.6M | $651.4M | ||
| Q1 24 | $170.2M | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.6M | $-29.4M |
| Free Cash FlowOCF − Capex | $15.0M | $-29.5M |
| FCF MarginFCF / Revenue | 46.9% | -51.6% |
| Capex IntensityCapex / Revenue | 11.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.0M | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.6M | $-29.4M | ||
| Q3 25 | $14.6M | $-31.6M | ||
| Q2 25 | $13.8M | $-15.3M | ||
| Q1 25 | $-24.7M | $-33.1M | ||
| Q4 24 | $21.6M | $-1.8M | ||
| Q3 24 | $13.3M | $-14.6M | ||
| Q2 24 | $16.0M | $-6.9M | ||
| Q1 24 | $-24.1M | $7.6M |
| Q4 25 | $15.0M | $-29.5M | ||
| Q3 25 | $13.8M | $-31.8M | ||
| Q2 25 | $13.4M | $-15.6M | ||
| Q1 25 | $-25.1M | $-33.6M | ||
| Q4 24 | $19.9M | $-2.0M | ||
| Q3 24 | $12.9M | $-14.7M | ||
| Q2 24 | $15.6M | $-7.0M | ||
| Q1 24 | $-24.7M | $7.6M |
| Q4 25 | 46.9% | -51.6% | ||
| Q3 25 | 44.1% | -56.5% | ||
| Q2 25 | 43.6% | -29.6% | ||
| Q1 25 | -80.0% | -67.1% | ||
| Q4 24 | 62.2% | -3.8% | ||
| Q3 24 | 42.4% | -30.9% | ||
| Q2 24 | 50.4% | -13.9% | ||
| Q1 24 | -81.6% | 15.9% |
| Q4 25 | 11.4% | 0.2% | ||
| Q3 25 | 2.6% | 0.3% | ||
| Q2 25 | 1.5% | 0.6% | ||
| Q1 25 | 1.3% | 0.9% | ||
| Q4 24 | 5.3% | 0.4% | ||
| Q3 24 | 1.2% | 0.3% | ||
| Q2 24 | 1.1% | 0.2% | ||
| Q1 24 | 2.0% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 23.62× | — | ||
| Q2 25 | 7.22× | — | ||
| Q1 25 | -10.01× | — | ||
| Q4 24 | 13.34× | — | ||
| Q3 24 | 5.90× | — | ||
| Q2 24 | 6.00× | — | ||
| Q1 24 | -8.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
